ANTIDEPRESSANT FLUORINATED PROTHIADENE DERIVATIVES: 9-FLUORO AND 2,9-DIFLUORO DERIVATIVE OF 11-(3-DIMETHYLAMINOPROPYLIDENE)--6,11-DIHYDRODIBENZO[*b*,*e*]THIEPIN*

Miroslav RAJŠNER, Emil SVÁTEK, Jan METYŠ and Miroslav PROTIVA Research Institute for Pharmacy and Biochemistry, 130 60 Prague 3

Received March 18th, 1981

6-Fluorophthalide (IV), obtained from 6-aminophthalide by the Schiemann method, was transformed by reactions with potassium salts of thiophenol and 4-fluorothiophenol to the acids Vand VI. Cyclization with polyphosphoric acid gave 9-fluoro- and 2,9-difluorodibenzo[b,e]thiepin--11(6H)-one (VII, VIII) which were treated with 3-dimethylaminopropylmagnesium chloride and afforded the tertiary alcohols IX and X. Dehydration by heating with dilute hydrochloric acid resulted in the title compounds II and III whose IR spectra indicated the *E*-configuration. Both compounds showed properties of tricyclic antidepressants being, however, less active than prothiadene (I) in the tests for the antireserpine activity.

It has been established that in the series of tricyclic neuroleptics the fluorination in some positions of the aromatic nuclei is connected with prolongation of the action and leads to deriving long-acting compounds which are suitable for oral $use^{1,2}$. In the series of analogues of the antidepressant 11-(3-dimethylaminopropylidene)--6,11-dihydrodibenzo[*b,e*]thiepin (*I*) (prothiadene, dosulepin, dothiepin) (ref.³⁻⁶), the influence of fluorination has not yet been investigated systematically from this point of view though syntheses and properties of the 2-fluoro derivative^{3,6-9} and 3,8-difluoro derivative of prothiadene¹⁰ have been described. In the present communication we report on the synthesis and pharmacological properties of the title compound *II* and *III*, *i.e.* the 9-fluoro and 2,9-difluoro derivatives of prothiadene.



^{*} Part CLXI in the series Neurotropic and Psychotropic Agents; Part CLX: This Journal 46, 2729 (1981).

Collection Czechoslovak Chem. Commun. [Vol. 47] [1982]

Rajšner, Svátek, Metyš, Protiva:

6-Aminophthalide^{7,11} was converted by diazotization and treatment with fluoroboric acid to the diazonium fluoroborate which was processed by the Schiemann reaction¹², *i.e.* by the thermic decomposition to 6-fluorophthalide (IV) which was obtained in a rather poor yield. Its heating with thiophenol or 4-fluoro-thiophenol¹³ in the presence of potassium carbonate to 120°C gave the acids V and VI. This modified procedure proved more suitable than the usual reaction of the phthalide IV with the sodium salt of the corresponding thiophenol, used in many cases heterofore⁷. The acids V and VI were cyclized by heating with polyphosphoric acid to 120–130°C; the ketones VII and VIII resulted in satisfactory yields and were



characterized by spectra. The following reactions with 3-dimethylaminopropylmagnesium chloride were carried out in tetrahydrofuran¹⁴ and gave the tertiary alcohols *IX* and *X*. The final step of the syntheses was the acid-catalyzed dehydration, effected by heating with dilute hydrochloric acid. The olefinic bases (*II* and *III*) obtained were oily in the crude state and represented evidently mixtures of geometric isomers. One of the isomers predominated which enabled in both cases the preparation of crystalline maleates. In the case of compound *III*, a homogeneous and crystalline base was separated; the base II could not be obtained in crystalline state. The IR spectra of both bases were recorded in carbon disulfide and the area of out-of-plane vibrations of C—H bonds of aromatic nuclei was used for the assignment of configuration. We started here from the findings made with the geometric isomers of prothiadene (I) (ref.⁵) (*E*-configuration of the predominating isomer, assigned here on the basis of the IR spectrum, was confirmed in the meantime by the X-ray crystallographic study¹⁵) and its 2-methyl derivative¹⁶. For compound II with the unsubstituted ring A, the considered diagnostic symptom is the absence of a satellite band at 743-744 cm⁻¹ which is typical for Z-prothiadene (Z-I) (ref.⁵). For this reason, *E*-configuration was assigned to compound II. For compound III the band at 879 cm⁻¹ was considered crucial, which is attributed to the solitary C—H bond in the ring A. On the basis of a comparison with corresponding bands in the spectra of the *E*-isomer of the 2-methyl derivative of prothiadene (873 cm^{-1}) and the corresponding Z-isomer (894 cm^{-1}) (ref.¹⁶), the *E*-configuration was assigned also to compound III. These configuration have to be considered tentative.

Compounds II and III were pharmacologically investigated and compared with prothiadene (I) (ref.⁶) and its 3,8-diffuoro derivative (XI) (ref.¹⁰). The compounds were administered in the form of salts but the doses given were calculated for bases.

Compound II: Intravenous toxicity in mice, $LD_{50} = 31.2 \text{ mg/kg}$. Rotarod test in mice, $ED_{50} = 7.2 \text{ mg/kg}$ *i.e.* An intravenous dose of 6 mg/kg potentiated the thiopental effect in mice (prolongation of the thiopental sleeping time to 220% in comparison with 100% of the control group). An *i.p.* dose of 40 mg/kg antagonized significantly the reserpine ptosis in mice. An oral dose of 100 mg/kg antagonized significantly the ulcerogenic effect of reserpine in rats (simultaneous administration with reserpine); the effect of a dose of 50 mg/kg was statistically insignificant. An oral dose of 100 mg/kg did not antagonize the cataleptic action of perphenazine (administered 1 h or 24 h before perphenazine). A dose of 10 mg/kg *s.c.* did not influence the tremor in mice elicited with arecoline (20 mg/kg *s.c.*). The antinociceptive action of oxotremorine (0·15 mg/kg *s.c.*) in mice was antagonized with a dose of 10 mg/kg *s.c.* only in 20% animals.

Compound III: $LD_{50} = 42.8 \text{ mg/kg}$ *i.v.*; toxic doses brought about central depression and convulsions. Rotarod test in mice, $ED_{50} = 30 \text{ mg/kg}$ *i.v.* (maximum in 5 min after the administration). Thiopental potentiation, a dose of 8.5 mg/kg *i.v.* prolonged the thiopental sleeping time to 250%. Reserptine ptosis in mice was antagonized significantly by a dose of 40 mg/kg *i.p.* An oral dose of 50 mg/kg antagonized significantly the ulcerogenic effect of reserptine in rats (administered simultaneously with reserptine). An oral dose of 100 mg/kg antagonized the cataleptic effect of rephenazine in rats (administered 24 h before perphenazine). This anticataleptic effect is not related to a trihexyphenidyl-like anticholinergic-antiparkinsonic action. The nature and importance of the anticataleptic action of prothiaden has been investigated more thoroughly¹⁷⁻¹⁹.

Compound XI (cf.¹⁰): $LD_{50} = 39.4 \text{ mg/kg}$ *i.v.* Rotarod test in mice, $ED_{50} = 30 \text{ mg/kg}$ *i.v.* (maximum activity in 10 min after the administration). Thiopental potentiation, a dose of 8 mg/kg *i.v.* prolonged the thiopental sleeping time to 220%. Reserpine ptosis in mice was not antagonized significantly by a dose of 40 mg/kg *i.p.* The ulcredgenic effect of reserpine in rats was not influenced by a dose of 50 mg/kg orally (administered simultaneously with reserpine) or 24 h before reserpine). A dose of 100 mg/kg orally, however, antagonized significantly the cataleptic action of perphenazine (administered either 1 h of 24 h before perphenazine). Doses of 10 mg/kg *s.c.*

did influence neither the arecoline (20 mg/kg s.c.) tremor in mice nor the antinociceptive action of oxotremorine (0.15 mg/kg s.c.) in mice.

In conclusion, compounds II, III and XI have in general the character of tricyclic antidepressants with antireserpine and anticataleptic activities lower than those of prothiadene (I). Neither the central depressant nor the antireserpine effects did show reliable prolongation in time.

Compounds II and III were also tested for antimicrobial activity in vitro (Dr J. Turinová, bacteriological department of this institute); microorganisms and the minimum inhibitory concentrations in μ g/ml (unless they exceed 100 μ g/ml) are given: Streptococcus β-haemolyticus, III 100; Streptococcus faecalis, III 100; Staphylococcus pyogenes aureus, III 50; Pseudomonas aeruginosa, III 100; Proteus vulgaris, III 100; Mycobacterium tuberculosis H37Rv, II 50, III 25; Saccharomyces pasterianus, II 50, III 100; Trichophyton mentagrophytes, II 50, III 50; Candida albicans, II 100, III 100; Aspergillus niger, II 100, III 100.

EXPERIMENTAL

The melting points of analytical preparations were determined in the Kofler's block and are not corrected; the samples were dried *in vacuo* of about 70 Pa over P_2O_5 at room temperature or at 77°C. The UV spectra (in methanol) were recorded with a Unicam SP 8000 spectrophotometer, the IR spectra (KBr) with a Unicam SP 200G spectrophotometer and most of the ¹H-NMR spectra (in C²HCl₃) with a ZKR 60 (Zeiss, Jena) spectrometer. The homogeneity of the compounds was checked by thin layer chromatography on silica gel.

6-Fluorophthalide (IV)

A mixture of 61.4 g 6-aminophthalide^{7,11}, 90 ml hydrochloric acid and 40 ml water was cooled to 0°C and diazotized under stirring with a solution of 31.0 g NaNO2 in 60 ml water added dropwise over a period of 1 h. After further 30 min stirring at 0°C, a solution of fluoroboric acid (prepared from 111 g 40% H_2F_2 and 34 g H_3BO_3) was added under continual cooling. After 15 min of stirring and 30 min of standing at room temperature, the precipitated diazonium fluoroborate was filtered, washed with water, ethanol and ether, and dried in vacuo over P_2O_5 . The product obtained (84.6 g) was divided into three parts and decomposed by heating using a direct flame (under reflux); the decomposition was considered complete when the gas formation ceased. The residues were extracted with boiling chloroform, the extracts were combined, filtered with charcoal and evaporated. The residue was chromatographed on a column of 550 g neutral Al_2O_3 (activity II). Benzene eluted some less polar impurities and elution with chloroform gave 10.9 g (18%) product, m.p. 106-108°C (benzene). IR spectrum: 835, 885 (2 adjacent and solitary Ar—H), 1 053 (C—O), 1 250 (Ar—F), 1 500, 1 612, 1 630 (Ar), 1 765 cm⁻¹ (ArCOO of the lactone), ¹H-NMR spectrum: δ 7·30–7·80 (m, 3 H, Ar–H), 5·48 and 5·25 (2 d, J = 12.0 Hz, 2 H, ArCH₂O). For C₈H₅FO₂ (152·1) calculated: 63·16% C, 3·31% H; found: 63·36% C, 3.44% H.

5-Fluoro-2-(phenylthiomethyl)benzoic Acid (V)

A stirred mixture of 6.5 g IV and 5.2 g thiophenol was heated to 120°C and slowly treated with 6.0 g K₂CO₃. The solidified mixture was heated for 30 min to 120°C, cooled, dissolved in 250 ml warm water, the solution was filtered and the filtrate acidified with hydrochloric acid. The pre-

Neurotropic and Psychotropic Agents

cipitated product was filtered after standing overnight, washed with water and dried *in vacuo*; 9·7 g (87%), m.p. 90-92°C. Analytical sample, m.p. 91-93°C (benzene-light petroleum). For $C_{14}H_{11}FO_2S$ (262·3) calculated: 64·10% C, 4·23% H, 7·24% F, 12·23% S; found: 64·15% C, 4·28 H, 7·16% F, 12·18% S.

5-Fluoro-2-(4-fluorophenylthiomethyl)benzoic Acid (VI)

A mixture of 5·1 g *IV*, 4·3 g 4-fluorothiophenol¹³ and 4·6 g K₂CO₃ was slowly heated to 120°C and kept for 40 min at this temperature. Processing like in the preceding case gave 7·8 g (83%) crude product, m.p. 116–118°C. Analytical sample, m.p. 119–120°C (benzene–light petroleum). IR spectrum: 845, 885 (2 adjacent and solitary Ar–H), 925, 2 565, 2 585, 2 680 (COOH), 1 225 (Ar–F), 1 495, 1 590 (Ar), 1 690 cm⁻¹ (ArCOOH). For C₁₄H₁₀F₂O₂S (280·3) calculated: (Ar–G), 3·60% H, 13·56% F, 11·43% S; found: 60·06% C, 3·70% H, 13·33% F, 11·50% S.

9-Fluorodibenzo[b,e]thiepin-11(6H)-one (VII)

Polyphosphoric acid was prepared from 50 g P_2O_5 and 30 ml 85% H₃PO₄ and heated to 120 to 130°C. Under stirring, 9·7 g V were added and the mixture was heated for 1 h to 130°C. After partial cooling it was decomposed with ice and water, the product extracted with chloroform, the extract was washed with 5% NaOH, dried with K₂CO₃, filtered with charcoal and evaporated; 8·8 g (90%) crude product, m.p. 89–92°C. Analytical sample, m.p. 92–93°C (ethanol). UV spectrum: λ_{max} 240·5 nm (log ϵ 4·32), infl. 264·5 nm (4·00), 354 nm (3·58). IR spectrum: 731, 800, 852, 860, 888 (4 and 2 adjacent and solitary Ar—H), 1 291 (CO), 1 487, 1 585 (Ar), 1 650 cm⁻¹ (ArCOAr). ¹H-NMR spectrum (Tesla BS 487C, 80 MHz): δ 8·15 (m, 1 H, 1-H), 7·00–7·40 (m, 6 H, remaining Ar—H), 3·97 (s, 2 H, ArCH₂S). ¹⁹F-NMR spectrum (in CHCl₃, $\delta_{CFCl_3} = 0$): δ -114·8 (m). For C₁₄H₉FOS (244·3) calculated: 68·83% C, 3·71% H, 7·78% F, 13·13% S; found: 68·73% C, 3·87% H, 7·58% F, 13·12% S.

2,9-Difluorodibenzo[b,e]thiepin-11(6H)-one (VIII)

Cyclization of 7.8 g VI with polyphosphoric acid (from 60 g P_2O_5 and 40 ml 85% H_3PO_4) by heating for 1.5 h to 120°C was carried out similarly like in the preceding case; processing gave 7.1 g (97%) crude product, m.p. 111–113°C. Analytical sample, m.p. 116–118°C (tehanol). UV spectrum: λ_{max} 239 nm (log ε 4.28), infl. 263·5 nm (3·96), 359 nm (3·61). IR spectrum: 840, 899 (2 adjacent and solitary Ar—H), 1270 (Ar—F), 1 600 (Ar), 1 645 cm⁻¹ (ArCOAr). ¹H-NMR spectrum: δ 6·90–8·05 (m, 6 H, Ar—H), 3·98 (s, 2 H, ArCH₂S). For C1₄H₈F₂OS (262·3) calculated: 64·11% C, 3·07% H, 14·49% F, 12·23% S; found: 64·34% C, 3·12% H, 14·38% F, 12·36%S.

9-Fluoro-11-(3-dimethylaminopropyl)-6,11-dihydrodibenzo[b,e]thieptn-11-ol (IX)

Grignard reagent was prepared by a reaction of 1.4 g Mg with 7.0 g 3-dimethylaminopropyl chloride in 20 ml tetrahydrofuran (the reaction was started with a small quantity of iodine and 2 drops 1,2-dibromoethane) and refluxed for 1 h. After cooling the stirred reagent was treated dropwise with a solution of 7.1 g *VII* in 15 ml tetrahydrofuran over 5 min (cooling with cold water). The mixture was stirred for 1 h at room temperature, cooled with ice and decomposed with 35 ml 20% solution of NH₄Cl. The product was extracted with chloroform, the extract was washed with water, dried with K_2CO_3 and evaporated. The residue was crystallized from 20 ml cyclohexane; 6-0 g (62%), m.p. 116–120°C. Analytical sample, m.p. 121–123°C (ethanol). IR spectrum: 752, 825, 885 (4 and 2 adjacent and solitary Ar–H), 1 122 (R₃C–OH), 1 253

Rajšner, Svátek, Metyš, Protiva:

(Ar—F), 1 482, 1 556, 1 583, 1 607 (Ar), 2 600 cm⁻¹ (OH···N). ¹H-NMR spectrum (Tesla BS 487C, 80 MH2): δ 8·00 (m, 1 H, 1-H), 7·70 (q, $J = 12\cdot0$ (H—F); 2·0 Hz, 1 H, 10-H), 6·70—7·20 (m, 5 H, remaining Ar—H), 4·56 and 3·75 (2 d, $J = 14\cdot0$ Hz, 2 H, ArCH₂S), 1·30—2·50 (m, 6 H, 3 CH₂ of the side chain), 2·24 (s, 6 H, CH₃NCH₃). For C₁₉H₂₂FNOS (331-5) calculated: 68:85% C, 6·69% H, 4·23% N, 9·67% S; found: 68:88% C, 6·68% H, 4·37% N, 9·38% S.

2,9-Difluoro-11-(3-dimethylaminopropyl)-6,11-dihydrodibenzo[b,e]thiepin-11-ol (X)

Similarly like in the preceding case, the Grignard reagent was prepared from 1.3 g Mg and 6.5 g 3-dimethylaminopropyl chloride in 20 ml tetrahydrofuran and was reacted with a solution of 7.0 g VIII in 35 ml tetrahydrofuran. Similar processing gave 6.6 g (71%) product, m.p. 112 to 114°C (cyclohexane). Analytical sample, m.p. 113–115°C (ethanol). IR spectrum: 820, 840, 900 (2 adjacent and solitary Ar—H), 1125 (R₃C—OH), 1 268 (Ar—F), 1495, 1 605 (Ar), 2 490 cm⁻¹ (OH…N). ¹H-NMR spectrum: δ -50–8.00 (m, 6 H, Ar—H), 4.45 and 3.70 (2 d, J = 140 Hz, 2 H, ArCH₂S), 2.12 (s, 6 H, CH₃NCH₃), 1.00–2.50 (m, 7 H, 3 CH₂ of the side chain and OH). For C₁₉H₂₁F₂NOS (349.4) calculated: 65.30% C, 6.06% H, 10.87% F, 4.01% N, 9.18% S; found: 65-25% C, 5-99% H, 10.75% F, 3.78% N, 9.44% S.

9-Fluoro-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo[b,e]thiepin (II)

A mixture of 6·0 g *IX* and 90 ml 1 : 2 dilute hydrochloric acid was refluxed for 30 min. After cooling it was diluted with water, made alkaline with NH₄OH and extracted with ether. The extract was filtered with charcoal, the filtrate dried with K_2CO_3 and evaporated. The oily mixture of bases (5·6 g) was dissolved in 24 ml ethanol and the solution was neutralized with a solution of 2·2 g maleic acid in 45 ml ether. Standing overnight afforded 6·0 g (77%) hydrogen maleate, m.p. 150–152°C (ethanol–ether). UV spectrum: infl. 226 nm (log ϵ 4·44), 260 nm (3·99), λ_{max} 306 nm (3·37). IR spectrum: 729, 755, 765, 824, 859, 865, 882 (4 and 2 adjacent and solitary Ar—H), 1573,1579, 1610 (Ar), 1695 (COO⁻), 2360 cm⁻¹ (NH⁺). ¹H-NMR spectrum (Tesla BS 487 C, 80 MHz, C²H₃SOC²H₃): δ 6·80–7·60 (m, 7 H, Ar—H), 6·00 (s, 2 H, CH=CH of maleic acid), 5·88 (t, $J = 6\cdot0$ Hz, 1 H, C=CH), 4·75 and 3·70 (2 d, $J = 14\cdot0$ Hz, 2 H, ArCH₂S), 3·16 (t, $J = 6\cdot0$ Hz, 2 H, CH₂N), 2·68 (s, 6 H, CH₃NCH₃), 2·25 (m, 2 H, remaining CH₂ in the side chain). For C₂₃H₂₄FNO4s (429-5) calculated: 64·31% C, 5·63% H, 3·26% N; found: 64·57% C, 5·96% H, 3·24% N.

Decomposition of the pure maleate with NH₄OH and extraction with ether gave the homogeneous oily base *II* to which the *E*-configuration was assigned on the basis of the IR spectrum (CS₂): 692, 712, 730, 750, 763, 782, 820, 844, 866, 887 cm⁻¹.

2,9-Difluoro-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenzo[b,e]thiepin (III)

Compound X (1-2 g) was dehydrated by refluxing with 20 ml 1:1 dilute hydrochloric acid for 30 min. Processing like in the preceding case gave 1-1 g (100%) base which crystallized from light petroleum, m.p. $62-66^{\circ}$ C. Two recrystallizations from light petroleum gave a homogeneous base, m.p. $71-72^{\circ}$ C, to which the *E*-configuration was assigned on the basis of the IR spectrum (CS₂): 719, 758, 764, 780, 806, 821, 866, 867, **879** cm⁻¹; in KBr: 815, 820, 838, 858, 888, 895 (2 adjacent and solitary Ar—H), 1 498, 1 574, 1 590, 1 604 cm⁻¹ (Ar). ¹H-NMR spectrum: δ 6·60-7·50 (m, 6 H, Ar—H), 5·95 (t, 1 H, C=CH), 4·85 and 3·32 (2 d, *J* = 14·0 Hz, 2 H, Ar. .CH₂S), *c* 2·25 (m, 4 H, 2 CH₂ of the side chain), 2·11 (s, 6 H, CH₃NCH₃). For C₁₉H₁₉F₂NS (331·4) calculated: 68·85% C, 5·78% H, 11·47% F, 4·23% N, 9·67% S; found: 69·29% C, 5·84% H, 11·36% F, 4·25% N, 9·74% S.

Collection Czechoslovak Chem. Commun. [Vol. 47] [1982]

70

Hydrogen maleate, m.p. 184–185°C with decomposition (aqueous ethanol). For $C_{23}H_{23}F_2$. NO₄S (447·5) calculated: 61·73% C, 5·18% H, 8·49% F, 3·13% N, 7·17% S; found: 61·94% C, 5·29% H, 8·20% F, 3·19% N, 6·90% S.

¹H-NMR spectra were recorded and interpreted by Dr J. Holubek (department of physical chemistry of this institute). The intermediates were prepared by Mr F. Mikšik. The analyses were carried out by Mrs J. Komancová, Mrs A. Slaviková, Mr M. Čech, Mr K. Havel and Mr J. Kominek (analytical department of this institute).

REFERENCES

- 1. Protiva M.: 5th Conf. Org. Chem., Smolenice, Apr. 1976; Proc. Conf., p. 72 (Pub. 1976).
- 2. Protiva M.: Pharmazie 34, 274 (1979).
- 3. Protiva M., Rajšner M., Seidlová V., Adlerová E., Vejdělek Z. J.: Experientia 18, 326 (1962).
- 4. Rajšner M., Protiva M.: Česk. Farm. 11, 404 (1962).
- 5. Rajšner M., Svátek E., Metyšová J., Protiva M.: This Journal 34, 1963 (1969).
- 6. Metyšová J., Metyš J., Votava Z.: Arzneim.-Forsch. 13, 1039 (1963).
- 7. Rajšner M., Seidlová V., Protiva M.: Česk. Farm. 11, 451 (1962).
- Protiva M., Rajšner M., Seidlová V., Vejdělek Z., Metyšová J.: Czech 107.632 (Appl. 24.03.62) Chem. Abstr. 60, 1718 (1964).
- Protiva M., Rajšner M., Votava Z., Metyšová J., Adlerová E., Seidlová V., Vejdělek Z. (Spofa): Fr. 1 332 145 (Czech. Appl. 08.06.61 and 24.03.62); Chem. Abstr. 60, 2916 (1964).
- 10. Rajšner M., Protiva M.: This Journal 32, 2021 (1967).
- 11. Hoenig M.: Ber. Deut. Chem. Ges. 18, 3447 (1885).
- 12. Roe A.: Org. Reactions 5, 193 (1949).
- 13. Rajšner M., Metyšová J., Svátek R., Mikšík F., Protiva M.: This Journal 40, 719 (1975).
- Protiva M., Rajšner M., Adlerová E., Seidlová V., Vejdělek Z. J.: This Journal 29, 2161 (1964).
- 15. King T. J.: Unpublished results.
- 16. Rajšner M., Metyš J., Svátek E., Protiva M.: This Journal 34, 1015 (1969).
- 17. Metyšová J., Metyš J., Dlabač A.: Activ. Nerv. Super. 20, 55 (1978).
- 18. Metyšová J., Metyš J.: Česk. Fysiol. 27, 53 (1978).
- 19. Valchář M., Metyš J., Metyšová J., Dlabač A.: Activ. Nerv. Super. 20, 54 (1978).

Translated by the author (M. P.).